All updates
All updates
today 43JAMA评分1515 STAT News评分3636 STAT+: Doctors are giving generously to doctors running for office
STAT News评分2525 STAT+: Animosity in North Carolina, and MA shooting stars
监管与产业动态评分55 Targeting Histone Lysine Acetylation in Cancer: From KAT Inhibitors to Translational Biomarkers - Fierce Biotech
顶刊论文（社媒热度）评分4040 Ten years, tens of millions of cells.
The Lancet评分1818 [Correspondence] Prioritising the future of youth is an urgent political choice
Nature Biotechnology评分2222 Proteomic aging clocks go to trial
BioSpace评分3838 Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
Nature评分3131 In the AI era, coding means thinking like a systems architect
监管与产业动态评分3939 What biotechnology can teach policymakers about how to regulate AI
监管与产业动态评分3232 Biotech markets: Pause before the storm? A BioCentury podcast
监管与产业动态评分22 From Data Rich to Decision Ready in Life Sciences - Fierce Pharma
监管与产业动态评分2727 How 'people power' and business transformed medicine, but created a whole new set of risks
监管与产业动态评分1616 Why Medical Affairs Is Becoming Biopharma’s Third Pillar - Fierce Pharma
监管与产业动态评分88 How data is reshaping rare disease media strategy - Fierce Pharma
监管与产业动态评分44 Why AI and Precision Matter in Pharma Commercialization - Fierce Pharma
监管与产业动态评分55 Beyond Data: Understanding the “Why” Behind HCP Decisions - Fierce Pharma
监管与产业动态评分99 Why Medical Teams Must Lead DOL Strategy - Fierce Pharma
监管与产业动态评分99 Why AI’s Biggest Value in Pharma Is Confidence - Fierce Pharma
监管与产业动态评分88 Why Timing Has Become HCP Marketing's Biggest Challenge - Fierce Pharma
监管与产业动态评分1111 RevHealth’s Chris Cullmann on AI and Human-Centered Pharma - Fierce Pharma
监管与产业动态评分1212 How Ohio Is Building a Biopharma Growth Engine - Fierce Pharma
监管与产业动态评分66 Why MRC Accreditation Is Just the First Step - Fierce Pharma
监管与产业动态评分55 AI, Data and the New Rules of HCP Marketing - Fierce Pharma
监管与产业动态评分77 Why Patient Voice Must Shape Pharma Strategy - Fierce Pharma
监管与产业动态评分44 Beyond the Pharmacy Counter: Inmar's Data Advantage - Fierce Pharma
监管与产业动态评分1111 AI-Powered Brand Sites Are Changing Patient Engagement - Fierce Pharma
监管与产业动态评分2323 The pope has a lung nodule. What does this mean? And what's the risk of cancer?
监管与产业动态评分3636 Insufficient evidence to back medical cannabis for insomnia
中文产业新闻Chinese source评分3434 人类细胞图谱十周年综述提出 HCA 2.0 路线图：十年编目 100 亿细胞并构建"虚拟组织模型"
中文产业新闻Chinese source评分2626 Nature系列综述：下一代免疫细胞衔接器瞄准自身免疫病B细胞深度清除
顶刊论文（社媒热度）评分3737 Heart Transplant for Advanced Heart Failure: A Review.
顶刊论文（社媒热度）评分1616 In Science Journals.
The Lancet评分4040 [Comment] Hepatitis C—is discrimination preventing elimination?
The Lancet评分3636 [Comment] Tailoring levels of evidence in trials comparing common treatments
Nature Biotechnology评分2020 Five questions with Bowen Li
Nature Biotechnology评分3535 Biotech news from around the world
Nature Biotechnology评分88 Genome editing
Nature Biotechnology精选评分6969 Engrafting human cortical organoids